Health Care & Life Sciences » Biotechnology | Celgene Corp.

Celgene Corp. | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
6,483
7,643
8,902
10,922
12,822
15,291
Cost of Goods Sold (COGS) incl. D&A
603
644
699
814
790
1,055
Gross Income
5,880
6,999
8,203
10,108
12,032
14,236
SG&A Expense
3,911
4,329
6,003
7,128
8,856
7,450
EBIT
1,969
2,669
-
2,980
3,176
6,786
Unusual Expense
91
125
164
413
1,328
1,223
Non Operating Income/Expense
123
79
298
39
219
29
Interest Expense
120
172
365
538
551
736
Pretax Income
1,665
2,327
2,024
2,373
4,314
4,832
Income Tax
216
328
422
373
1,374
786
Consolidated Net Income
1,450
2,000
1,602
1,999
2,940
4,046
Net Income
1,450
2,000
1,602
1,999
2,940
4,046
Net Income After Extraordinaries
1,450
2,000
1,602
1,999
2,940
4,046
Net Income Available to Common
1,450
2,000
1,602
1,999
2,940
4,046
EPS (Basic)
1.69
2.39
1.94
2.49
3.64
5.51
Basic Shares Outstanding
828
803
792
777
779
716
EPS (Diluted)
1.68
2.39
1.94
2.49
3.64
5.51
Diluted Shares Outstanding
861
836
825
803
809
734
EBITDA
2,343
3,043
2,599
3,484
3,646
7,420
Non-Operating Interest Income
29
34
55
388
142
34
Equity in Affiliates (Pretax)
-
-
-
6
-
-

About Celgene

View Profile
Address
86 Morris Avenue
Summit New Jersey 07901
United States
Employees -
Website http://www.celgene.com
Updated 07/08/2019
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company's products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.